With a substantially high positive detection rate of SARS-CoV-2 utilizing IgM antibody ELISA assays and the possibility of achieving even higher sensitivity by combining antibodies detection with polymerase chain reaction, IgM antibodies testing has become a viable accessory in the diagnosis of COVID-19 in its acute phase (Choteau et al. 2022; Guo et al. 2020; Zhao et al. 2020). Here, CD40LG is linked to COVID-19.